Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
18F-BMS-986327 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part 1 | EXPERIMENTAL | - |
| Part 2 | EXPERIMENTAL | - |
| Part 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 18F-BMS-986327 | DIAGNOSTIC_TEST | Imaging Agent |
Inclusion Criteria: All Participants: · Body mass index of 18.0 to 34.0 kg/m\^2, inclusive, and body weight ≥ 50 kg Healthy Participants: * Male and female healthy volunteers ages 18 or age or older * No clinically significant deviation from normal in medical history, physical examination, elect...
18F-BMS-986327 is an investigational radiopharmaceutical being developed by Bristol-Myers Squibb Company (BMY). It is currently in Phase 1 clinical development for use in healthy participants and in patients with idiopathic pulmonary fibrosis (IPF). The drug is being studied for its safety, tolerability, kinetics, and repeatability.
18F-BMS-986327 is being studied for use in healthy participants and in patients with idiopathic pulmonary fibrosis (IPF). The ongoing clinical trial evaluates its safety, tolerability, kinetics, and repeatability in these populations. It is an investigational drug and has not been approved by regulatory authorities.
18F-BMS-986327 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical research to evaluate the drug's safety and other properties in a Phase 1 study.
18F-BMS-986327 is in Phase 1 clinical development. A Phase 1 study has been completed, which evaluated the drug in healthy participants and in patients with idiopathic pulmonary fibrosis (IPF). The drug is investigational and has not been approved by the FDA or other regulatory agencies.
18F-BMS-986327 has one completed clinical trial, registered under the identifier NCT04069143. The study, titled "A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327," enrolled 14 participants in the United States and included healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF).
18F-BMS-986327 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A completed Phase 1 study evaluated its safety, tolerability, kinetics, and repeatability in healthy participants and in patients with idiopathic pulmonary fibrosis (IPF), but the drug remains under investigation.